WUHU, China, Nov. 28, 2025 /PRNewswire/ — Following the global success of the environmental documentary Return of the Cheetah, JETOUR has once again joined hands with Discovery Channel and the Cheetah Conservation Fund (CCF) to relaunch the “Return of the Cheetah” initiative.
This second phase focuses on the Horn of Africa — one of the world’s key hotspots for cheetah trafficking — calling for global attention and collective action to protect endangered wildlife and promote coexistence between people and nature.
Continuing the Spirit of Return of the Cheetah
In 2024, JETOUR and Discovery co-produced the documentary Return of the Cheetah, filmed in Namibia, which followed CCF’s rescue and rehabilitation work and raised global awareness of endangered species.
Building on that success, JETOUR is extending the film’s message from screen to field, channeling corporate responsibility into real conservation action.
In 2025, the renewed campaign turns its focus to the Horn of Africa. Working with the Cheetah Conservation Fund, JETOUR will help raise awareness about the threats facing cheetahs in the region and support community education programs aimed at reducing illegal wildlife trade. JETOUR also announced the adoption of rescued cheetahs to assist rehabilitation and long-term care efforts.
G700 Leads the Journey: Practicing “Travel + Responsibility”
The G700 will accompany this year’s journey, combining off-road performance with environmental purpose. As the first premium model under JETOUR’s “Travel +” strategy, the G700 represents responsible exploration. Its powerful all-terrain capabilities, combined with intelligent driving systems, ensure safe operation. The energy management system provides sustainable power support for the rescue team, ensuring continuous operation in remote areas and showcasing JETOUR’s innovation in smart and new-energy mobility.
For JETOUR, travel means more than exploration — it is also a commitment to giving back. From cheetah support programs in Africa to education initiatives in the Middle East and inclusive sports in South America, JETOUR continues to demonstrate social responsibility through meaningful action.
Sustaining the Commitment to a Greener Future
Looking ahead, JETOUR remains committed to its global vision — In Somewhere, For Somewhere, Be Somewhere — connecting travel with sustainability.
As Return of the Cheetah reminds, protecting nature is not a single act but an ongoing journey. Through its “Travel + ESG” mission, JETOUR aims to inspire global awareness and ensure that every journey contributes to a greener, more sustainable planet.
SINGAPORE – Media OutReach Newswire – 28 November 2025 – As part of its commitment to enhancing community welfare in its operational areas, Asian Agri’s business unit PT Inti Indosawit Subur (PT IIS) has provided educational support and alternative economic assistance to two foster villages – Tri Mulya Jaya and Ukui Dua – in Ukui District, Pelalawan Regency, Riau. The assistance was officially handed over on 10 October 2025 at the Tri Mulya Jaya Village Hall.
In his remarks, Pengarapen Gurusinga, Regional Head of Riau at Asian Agri, a member of the Royal Golden Eagle (RGE) group of companies founded by Sukanto Tanoto, emphasised that this initiative is part of the company’s sustainability commitment under the Asian Agri 2030 Programme. “Asian Agri has a long-term vision outlined in the Asian Agri 2030 Programme, which is built on four main pillars, one of which is Inclusive Growth. Today’s activity reflects this pillar by supporting efforts to improve community welfare through expanded access to education and the development of micro-enterprises to foster self-reliance and competitiveness,” he said.
This programme reflects Asian Agri’s commitment to supporting children’s access to proper education and encouraging their enthusiasm for learning. Through the Bag-To-School initiative, a total of 22 educational support packages were distributed to students in Tri Mulya Jaya Village and Ukui Dua Village. The assistance comprised 10 packages for elementary school students, six for middle school students, and six for high school students, each containing a high-quality school bag, stationery, uniforms and shoes.
This support was warmly received by the community and local government. H. Narko, Regional Coordinator of the Ukui District Education Office, expressed his appreciation for Asian Agri’s contribution. “We hope parents will continue encouraging their children to attend school. Education may be free, but families still need to provide clothing and school supplies. That is why Asian Agri’s assistance is so meaningful as it helps ease the financial burden on families and strengthens children’s enthusiasm for learning. Never feel discouraged about pursuing education to higher levels,” he said.
Beyond educational assistance, Asian Agri is also committed to strengthening the local economy through the empowerment of micro, small, and medium enterprises (MSMEs). The company previously conducted outreach activities to help residents identify village commodities with economic potential and provided training on business development strategies. This support was further realised through the provision of livestock to Tri Mulya Jaya Village and Ukui Dua Village, with each village receiving six goats – two males and four females.
Ukui District Head, Joko Hadi Syaifudin Zuhri, expressed his gratitude for the initiative and hoped it would bring tangible benefits to the community. “May this livestock assistance serve as a starting point for improving the welfare of our people, especially in economic and health aspects. We hope the support will not only be accepted but also cared for and developed to deliver long-term benefits. Let us demonstrate that this assistance can thrive, grow and truly enhance the well-being of our residents,” he said.
Through this year’s Bag-To-School programme, Asian Agri will distribute a total of 265 educational packages to students across 28 villages in Riau, including 140 packages for elementary school students, 75 for junior high school students, and 50 for high school students. The programme also extends support to MSME development, assisting seven business groups across seven villages. Hashtag: #RGE #AsianAgri #CSR #Indonesia #Riau #education #MSME
The issuer is solely responsible for the content of this announcement.
About Asian Agri
Founded in 1979, Asian Agri is one of Indonesia’s foremost companies in crude palm oil production, managing over 100,000 hectares of oil palm plantations and employing over 20,000 people.
As a pioneer of the Indonesian Government’s Smallholder Transmigration Core Plantation Programme (PIR-Trans), Asian Agri has partnered with 30,000 scheme smallholders in Riau and Jambi, who collectively manage 60,000 hectares of oil palm plantations. The company also fosters partnerships with independent smallholders to enhance their welfare and drive socio-economic growth.
Committed to sustainable practices, Asian Agri upholds a zero-burning policy and implements plantation best management practices to help smallholders boost productivity, increase crop yields, and improve supply chain traceability while supporting their journey towards certification. Asian Agri’s mills leveraged advanced technology and self-generated green energy to minimize greenhouse gas emissions.
Asian Agri’s plantations, as along with their scheme smallholder plantations, are full Roundtable on Sustainable Palm Oil (RSPO) and International Sustainability & Carbon Certification (ISCC) certified, underscoring the company’s commitment to responsible and sustainable palm oil production.
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene’s onCARlytics (CF33-CD19) oncolytic virus and JW’s CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors.
The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers.
This approach represents a first-in-class “mark and kill” strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
The collaboration leverages JW’s commercial CAR-T infrastructure and Imugene’s clinical onCARlytics platform to generate preclinical and clinical data and inform further clinical development.
SYDNEY and SHANGHAI, Nov. 27, 2025 /PRNewswire/ — Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, today announced a co-development collaboration to evaluate the combination of Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s Carteyva®—a CD19-directed autologous CAR-T cell therapy—for patients with advanced solid tumors.
This collaboration includes preclinical in vitro and in vivo studies, followed by a Phase 1 investigator-initiated trial to be conducted exclusively in China at premier CAR-T clinical centers. The approach utilizes Imugene’s CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies—a transformative “mark and kill” strategy.
“This collaboration allows us to validate our onCARlytics platform in combination with an approved autologous CAR-T product,” said Leslie Chong, Managing Director and CEO of Imugene. “We believe Carteyva® which is already approved in blood cancer is an ideal choice, and this initiative enables us to generate impactful data efficiently while exploring a breakthrough treatment paradigm for solid tumours.”
With clear go/no-go decision points, and milestones, the collaboration ensures disciplined capital allocation while enabling strategic flexibility.
For more information please contact:
Leslie Chong Managing Director and Chief Executive Officer info@imugene.com
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
About JW Therapeutics (HKEX: 2126)
JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com.
SHENZHEN, China, Nov. 28, 2025 /PRNewswire/ — JMGO, a pioneer in optical technology, announced its official cooperation with Costco in North America. Currently, JMGO has entered Costco Canada and will enter Costco USA by the end of this year, marking a major milestone in the company’s North American retail expansion.
The JMGO N1S Ultimate sets a new benchmark for portable 4K projection, boasting a remarkable brightness of 3300 ISO lumens. Equipped with Google TV, it provides access to certified Netflix, over 10,000 apps, and 800 free channels. Its 360° horizontal and 135° vertical gimbal design ensures flexible placement. The N1S Ultimate can easily transform any room into a private theater.
N1S Infinity
For those prioritizing portability without sacrificing quality, the JMGO N1S Infinity delivers stunning visuals in a compact design. This model produces clear, detailed 4K UHD images at 2450 ISO Lumens, using the same cutting-edge MALC triple laser Optics for vibrant, true-to-life colors. Users could enjoy endless entertainment content.
PicoPlay+ Bundle (Costco-Exclusive)
The PicoPlay+ Bundle is now offered as a Costco-exclusive Bundle that includes a PicoPlay+ projector, a 100-inch portable screen, a 65W Type-C fast charging power bank tripod, and an HDMI cable, providing up to 4.5 hours of playback in Eco mode and offering a flexible, portable solution for both indoor and outdoor entertainment.
In Costco USA, besides the PicoPlay+ Bundle, the following two projectors can also be found at Costco in the US:
O2S Ultra with 120-inch Motorized ALR Floor Rising Screen
The O2S Ultra is JMGO’s most advanced compact ultra-short-throw triple laser projector, designed to redefine high-end home cinema. Powered by MALC™ 3.0 triple laser system, it delivers true 4K resolution with lifelike color accuracy and vivid brightness of 3600 ISO lumens. With an ultra-short-throw ratio of 0.16:1, O2S Ultra produces a 120-inch screen from only 9.76 inches off the wall, turning even tight spaces into a full home theater.
N3 4K with 100-Inch Portable Projector Screen
The N3 4K projector combines MALC™ 3.0 triple laser optics, optical zoom 1-1.3:1, dynamic gimbal control, and Google TV with Netflix built in for a premium home theater experience. Equipped with an integrated 360° horizontal and 160° vertical gimbal, JMGO Master Sound Hi-Fi audio and Dolby Audio, the N3 4K can be flexibly placed and provides an immersive audio-visual experience.
By entering Costco in the US and Canada, and following its Best Buy partnership, JMGO continues to strengthen its North American presence and bring high-quality projection experiences to more consumers.
To know more about JMGO products, please visit JMGO.com
About JMGO
Founded in 2011, JMGO has become a pioneer in intelligent projection technology, combining innovation, design, and user experience to redefine modern home entertainment. With a global presence spanning over 30 countries, JMGO continues to lead the laser projection industry through research-driven development and a commitment to immersive visual excellence.
BEIJING, Nov. 28, 2025 /PRNewswire/ — A news report from CRI Online:
As sapphire seas and skies become the backdrop for “I dos” and cityscapes blend into sweet ceremonies, destination weddings are emerging as a new trend among young couples. Leveraging its exceptional coastal scenery and unique urban charm, Weihai is transforming romance into economic vitality, steadily becoming a favored choice for couples across the country seeking a memorable destination wedding.
BEIJING, Nov. 28, 2025 /PRNewswire/ – A news report from CRI Online:
Weihai has introduced two new regulatory documents: the “Weihai Guidelines for Enterprise Name Registration Management” and the “Weihai Implementation Rules for Enterprise Name Dispute Resolution.” These measures mark a significant step in standardizing business name administration and establishing an efficient dispute resolution mechanism.
As a provincial-level pilot city for institutional innovation in enterprise name registration, Weihai has become the first in Shandong Province to achieve full-chain management of business name registration and efficient resolution of naming disputes. The reforms provide valuable practical experience for similar regulatory improvements across the province.
The new policies, jointly issued by the Weihai Administrative Approval Service Bureau and the Weihai Market Supervision Administration, represent a breakthrough in creating a more standardized and business-friendly registration environment.
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ — Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”, HKEX: 6990)’s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published in the journal of Annals of Oncology (Impact Factor: 65.4). This study provides the first evidence of sac-TMT’s potential significant clinical benefit for patients with advanced UC.
This publication is based on the efficacy and safety results of cohort 9 of a phase II MK-2870-001/KL264-01 study evaluating sac-TMT monotherapy in patients with advanced or metastatic UC and disease progression after chemotherapy and immune checkpoint inhibitors. Sac-TMT employs the only currently available irreversible conjugation technology, combined with the novel toxin – a topoisomerase I inhibitor KL610023 (T030). This enhances stability, ensuring greater release of the toxin T030 at tumor sites. It guarantees precise and potent tumor cell killing, achieving an effective balance between efficacy and safety. With its unique structural design, sac-TMT has demonstrated outstanding therapeutic potential in clinical studies.
The results showed that sac-TMT 5 mg/kg monotherapy every 2 weeks demonstrated promising antitumor activity in participants with heavily pretreated advanced or metastatic UC, with a manageable safety profile, warranting further evaluation of sac-TMT in this population.
As of data cutoff (February 17, 2025), 49 participants were treated with sac-TMT; 37 (76%) had received ≥2 prior lines of therapy. Median follow-up was 18.8 months. The confirmed ORR was 31% (sac-TMT as second-line therapy demonstrated a confirmed ORR of 50%) and the disease control rate was 71%. Median DOR was not reached, and the 12-month probability of sustained response was 53%. Median PFS was 5.5 months, with 12-month PFS rate was 29%. Safety with sac-TMT was manageable, the most frequent grade 3 or 4 treatment-related adverse events (AEs) (≥5%) were hematologic toxicities and stomatitis, with no febrile neutropenia events or grade 5 treatment-related AEs.
Professor Ye Dingwei, Vice President of Fudan University Shanghai Cancer Center, stated, “Traditional chemotherapy has limited efficacy for advanced or drug-resistant UC. The emergence of precision medicines like ADCs is breaking through treatment bottlenecks for patients with poor response to chemotherapy. We are delighted to observe the encouraging clinical outcomes achieved by the sac-TMT monotherapy regimen, particularly its outstanding efficacy even among heavily pretreated patients. This development injects new momentum into the treatment landscape for advanced UC and offers patients a more precise therapeutic option.”
About sac-TMT
Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as non-small cell lung cancer (NSCLC), breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.
In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).
To date, three indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting), EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy and EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy. Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. In addition, the sNDA for sac-TMT for the treatment of adult patients with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and was included in the priority review and approval process.
As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.
Winners’ efforts reaffirm that sustainability and business excellence are deeply interconnected
BALI, INDONESIA – Media OutReach Newswire – 28 November 2025 – The ACES Awards 2025 opened in Bali with a powerful first night dedicated to honouring Asia’s most credible and committed sustainability leaders.
Winners and distinguished participants of the ACES Awards 2025 gather at the InterContinental Bali Resort on November 27, 2025, to celebrate Day One, dedicated to recognizing excellence in sustainability across Asia.
With sustainability positioned as the cornerstone of this year’s programme, Day One of the Awards underscored the region’s rapid shift toward measurable, science-aligned, and transparent environmental and social practices.
“The 2025 Sustainability Award winners represent the strongest examples of responsible leadership in Asia today.
They have demonstrated discipline, transparency, and genuine long-term commitment to measurable environmental and social impact, said Dr Shanggari Balakrishnan, the CEO of MORS Group, organiser of the ACES Awards.
“Their efforts reaffirm that sustainability and business excellence are deeply interconnected, and we applaud their role in moving the region forward,” she added.
This year marked a historic milestone for the ACES Awards, which received 827 nominations from 32 countries, spanning more than 40 award categories.
Following 946 hours of evaluations by the ACES Council, 381 finalists were shortlisted, and 111 winners were recognised across the two-day ceremony.
Celebrating the 2025 Sustainability Winners
This year’s winners demonstrated strong governance systems, measurable reductions in carbon and waste intensity, large-scale circularity systems, water efficiency initiatives, biodiversity protection, and community development programmes.
Notable return winners include Maynilad Water Services, Inc., San Miguel Global Power Holdings Corp., CEBU LANDMASTERS, INC., Takeda Healthcare Philippines, Inc., BDO Unibank, and Danone Specialized Nutrition SEA.
Top winners for Day One included:
CPC Corporation, Taiwan – Top Sustainability Advocates in Asia (7th ACES win)
Globe Telecom – Asia’s Best Workplace of the Year (7th ACES win)
Development Bank of the Philippines – Top Community Centric Companies in Asia (3rd ACES win)
Foundever Philippines Corporation – Top Workplaces & Community Centric Companies (5th ACES win)
Henderson Land Development Company Limited – Asia’s Most Sustainable Company of the Year
ESG Pioneer Award
Highlight of the night included honouring one of Asia’s most respected voices in ESG transformation – Dr Jayanthi Desan, Co founder of BoomGrow and Advisor to ACES Council who was presented with the prestigious ESG Pioneer Award.
Recognised for pioneering a company which has brought together climate technology, sustainable innovation and commercial strategy, Dr Jayanthi’s relentless efforts proved that responsible growth and high performance can coexist.
A Benchmark for Responsible and Measurable Leadership
The Sustainability Category, a core pillar of the ACES framework, recognises corporations that demonstrate responsible, data-driven, and future-focused environmental and social leadership.
In 2025, the assessment criteria were strengthened to emphasise science-based targets, verification of measurable impact, circularity programmes, resource stewardship, and alignment to IFRS S1 and S2 sustainability disclosure standards.
With 147 companies shortlisted and 40 winners selected, the category recorded one of its most competitive years to date.
Judges highlighted that participating organisations demonstrated higher levels of reporting transparency, more robust carbon reduction pathways, and deeper long-term integration of sustainability into corporate planning.
Judging Insights: A New Era of Data-Driven Sustainability
The ACES Council evaluated submissions based on strategy clarity, governance strength, innovation, stakeholder engagement, and evidence-backed environmental and social outcomes.
A clear shift toward quantified impact, verifiable emissions pathways, and improved comparability of reporting was observed.
Companies also acknowledged the challenges of navigating multiple ESG frameworks.
However, the introduction of IFRS S1 and S2 has provided much-needed harmonisation, enhancing transparency and reporting efficiency across the region.
Winners distinguished themselves through authenticity, long-term resilience planning, transparent disclosures, and the ability to scale sustainability initiatives beyond compliance.
Setting the tone for ACES 2025
Day One of the Awards concluded with the conferral of the prestigious Visionary’s Gold Centaur, Maestro’s Onyx Centaur, and Virtuoso’s Black and Gold Centaur trophies, recognising companies with multi-year excellence.
The ceremony set a strong tone for Day Two, which spotlights Asia’s leadership and workplace champions.
The issuer is solely responsible for the content of this announcement.
MORS Group | ACES Awards
About the ACES Awards The Asia Corporate Excellence & Sustainability (ACES) Awards recognises outstanding leaders and organisations across Asia that demonstrate excellence in leadership, sustainability, and corporate responsibility. As a premier regional awards platform, ACES highlights companies and individuals that set industry benchmarks and contribute meaningfully to economic and social progress. Through its rigorous evaluation and broad regional reach, ACES continues to showcase best-in-class achievers shaping Asia’s corporate landscape.
About MORS Group MORS Group is a regional business intelligence and advisory organisation committed to advancing leadership, sustainability, and corporate excellence in Asia. Through strategic platforms and recognition programmes—including the ACES Awards—MORS Group supports organisations in elevating performance, strengthening governance, and fostering long-term growth. Its work enables companies and leaders to connect, gain insights, and drive purposeful impact across the region.
